Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP
May 10th 2022
Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.